IL33 and neoplasm: It was recently reported that IL-33 activates tumoral ILC2s that double the abundance of intratumoral CD103+ DCs, priming and recruiting CD8+ T cells into orthotopic pancreatic tumors to restrict tumor growth in mice [62].